OasisLMS

After the LUGPA 2025 GPCC Enduring Program, learners will be able to: 

• Describe the biological mechanisms and genetic factors involved in the development and progression of prostate cancer.
• Evaluate the current screening methods for prostate cancer, such as PSA testing and digital rectal exams, and understand their benefits and limitations.
• Describe the various diagnostic approaches, including imaging modalities (MRI, CT, PET scans) and biopsy techniques, as well as staging criteria for prostate cancer.
• Compare and contrast the various treatment options for localized and advanced prostate cancer, including surgery, radiation therapy, hormone therapy, chemotherapy, and emerging treatments.
• Develop strategies for managing the side effects and complications of prostate cancer treatments, including urinary incontinence, sexual dysfunction, and metabolic changes.
• Explore the latest research findings and future directions in prostate cancer, including advancements in genetic testing, immunotherapy, and personalized medicine. Review and appraise resources about legislation related to prostate cancer.

This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of PeerPoint Medical Education Institute and the LUPGA. PeerPoint Medical Education Institute is accredited by the ACCME to provide continuing medical education for physicians.

PeerPoint Medical Education Institute designates the enduring format for this educational activity for a maximum of 9.50 AMA PRA Category 1 Credits™. Physicians should only claim credit commensurate with the extent of their participation in the activities.

The Enduring approval period is: January 10, 2026 – January 10, 2029